Published: Oct 03, 2022 By Heather McKenzie BioSpace Say what you will about the $158,000 price tag on Amylyx’s newly minted Relyvrio or the worthiness of the CENTAUR trial, the FDA’s approval of its third-ever ALS drug has ignited the growing momentum in the space. Coming on the heels of Biogen and Eisai’s seeming breakthrough – and possible redemption of the anti-amyloid theory – in…
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that primarily affects motor neurons, leading to progressive muscle weakness and loss of voluntary muscle control. While…
ALS does not discriminate. People of every age, gender, race, ethnicity, religion, sexual orientation, and nationality are diagnosed with ALS. However, not everyone has the…
The NFL says it will allow players to wear protective soft-shell helmet covers known as…
Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an FDA approval for…
The clinic at East Tennessee State University Health is the only one in the state to offer free multidisciplinary care to ALS patients.
There has been a breakthrough in the research on the disease amyotrophic lateral sclerosis (ALS). Scientists at Umeå University report that the disease progression in…
In-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease drug Skyclarys has Wall Street giving Biogen another chance.
EverythingALS is a patient-focused non-profit, part of Peter Cohen Foundation (PCF) a 501(3)c organization. Our mission is to support efforts to care for ALS patients…
Interdisciplinary research team using AI, engineering, and knowledge of disease complications to create “CART” STONY BROOK, NY, April 25, 2024 – The debilitating disease of…
The former N.F.L. player has been living with A.L.S. for more than a decade. Sharing “the most lacerating and vulnerable times” in “A Life Impossible”…
